Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial.
Lee S. Rosen,David Gordon,Mary Kaminski,Anthony Howell,Andrew R. Belch,John R. Mackey,J. Apffelstaedt,Mohamad A. Hussein,Robert E. Coleman,Dirk J. Reitsma,Bee-Lian Chen,John J. Seaman +11 more
Reads0
Chats0
TLDR
In this article, the authors compared the long-term safety and efficacy of zoledronic acid with pamidronate in patients with bone lesions secondary to advanced breast carcinoma or multiple myeloma.Abstract:
BACKGROUND
The goal of the current study was to compare the long-term (25-month) safety and efficacy of zoledronic acid with pamidronate in patients with bone lesions secondary to advanced breast carcinoma or multiple myeloma.
METHODS
Patients (n = 1648) were randomized to receive 4 mg or 8 mg (reduced to 4 mg) zoledronic acid as a 15-minute infusion or to receive 90 mg pamidronate as a 2-hour infusion every 3–4 weeks for 24 months. The primary endpoint was the proportion of patients with at least 1 skeletal-related event (SRE), defined as pathologic fracture, spinal cord compression, radiation therapy, or surgery to bone. Secondary analyses included time to first SRE, skeletal morbidity rate, and multiple-event analysis. Hypercalcemia of malignancy (HCM) was included as an SRE in some secondary analyses.
RESULTS
After 25 months of follow-up, zoledronic acid reduced the overall proportion of patients with an SRE and reduced the skeletal morbidity rate similar to pamidronate. Compared with pamidronate, zoledronic acid (4 mg) reduced the overall risk of developing skeletal complications (including HCM) by an additional 16% (P = 0.030). In patients with breast carcinoma, zoledronic acid (4 mg) was significantly more effective than pamidronate, reducing the risk of SREs by an additional 20% (P = 0.025) compared with pamidronate and by an additional 30% in patients receiving hormonal therapy (P = 0.009). Zoledronic acid (4 mg) and pamidronate were tolerated equally well. The most common adverse events included bone pain, nausea, and fatigue.
CONCLUSIONS
Long-term follow-up data confirm that zoledronic acid was more effective than pamidronate in reducing the risk of skeletal complications in patients with bone metastases from breast carcinoma and was of similar efficacy in patients with multiple myeloma. Cancer 2003. © 2003 American Cancer Society.
DOI 10.1002/cncr.11701read more
Citations
More filters
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines
TL;DR: Lymphedema is a common complication after treatment for breast cancer and factors associated with increased risk of lymphedEMA include extent of axillary surgery, axillary radiation, infection, and patient obesity.
Journal ArticleDOI
Clinical Features of Metastatic Bone Disease and Risk of Skeletal Morbidity
TL;DR: Improved understanding of prognostic and predictive factors may enable delivery of a more personalized treatment for the individual patient and a more cost-effective use of health care resources.
Journal ArticleDOI
Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study
Alison Stopeck,Allan Lipton,Jean-Jacques Body,Guenther G. Steger,Katia Tonkin,Richard De Boer,Mikhail Lichinitser,Yasuhiro Fujiwara,Denise A. Yardley,María Viniegra,Michelle Fan,Qi Jiang,Roger Dansey,Susie Jun,Ada Braun +14 more
TL;DR: With the convenience of a subcutaneous injection and no requirement for renal monitoring, denosumab represents a potential treatment option for patients with bone metastases.
Journal ArticleDOI
Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma
David H. Henry,Luis Costa,François Goldwasser,Vera Hirsh,Vania Hungria,Jana Prausova,Giorgio V. Scagliotti,Harm Sleeboom,Andrew Spencer,Saroj Vadhan-Raj,Roger von Moos,Wolfgang Willenbacher,Penella J. Woll,Jianming Wang,Qi Jiang,Susie Jun,Roger Dansey,Howard S. Yeh +17 more
TL;DR: Denosumab was noninferior (trending to superiority) to ZA in preventing or delaying first on-study SRE in patients with advanced cancer metastatic to bone or myeloma and represents a potential novel treatment option with the convenience of subcutaneous administration and no requirement for renal monitoring or dose adjustment.
Journal ArticleDOI
Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology
William J. Gradishar,Benjamin O. Anderson,Jame Abraham,Rebecca Aft,Doreen M. Agnese,Kimberly H. Allison,Sarah L. Blair,Harold J. Burstein,Chau T. Dang,Anthony D. Elias,Sharon H. Giordano,Matthew P. Goetz,Lori J. Goldstein,Steven J. Isakoff,Jairam Krishnamurthy,Janice A. Lyons,P. Kelly Marcom,Jennifer M. Matro,Ingrid A. Mayer,Meena S. Moran,Joanne E. Mortimer,Ruth O'Regan,Sameer A. Patel,Lori J. Pierce,Hope S. Rugo,Amy M. Sitapati,Karen L. Smith,Mary Lou Smith,Hatem Soliman,Erica Stringer-Reasor,Melinda L. Telli,John H. Ward,Jessica Young,Jennifer L. Burns,Rashmi Kumar +34 more
TL;DR: The NCCN Guidelines specific to the workup and treatment of patients with recurrent/stage IV breast cancer are discussed in this article.
References
More filters
Journal ArticleDOI
Global cancer statistics
TL;DR: A substantial proportion of the worldwide burden of cancer could be prevented through the application of existing cancer control knowledge and by implementing programs for tobacco control, vaccination, and early detection and treatment, as well as public health campaigns promoting physical activity and a healthier dietary intake.
Journal ArticleDOI
Cox's Regression Model for Counting Processes: A Large Sample Study
TL;DR: In this article, the Cox regression model for censored survival data is extended to a model where covariate processes have a proportional effect on the intensity process of a multivariate counting process, allowing for complicated censoring patterns and time dependent covariates.
Journal ArticleDOI
Cancer statistics, 2001.
TL;DR: Estimates of the number of new cancer cases and deaths expected in the US in the current year and the most recent data on cancer incidence, mortality, and survival reveal large disparities in cancer incidence and mortality across racial/ethnic groups.
Journal ArticleDOI
A Randomized, Placebo-Controlled Trial of Zoledronic Acid in Patients With Hormone-Refractory Metastatic Prostate Carcinoma
Fred Saad,Donald M. Gleason,Robin Murray,Simon Tchekmedyian,Peter Venner,Louis Lacombe,Joseph L. Chin,Jeferson J. Vinholes,J. Allen Goas,Bee Chen +9 more
TL;DR: Zoledronic acid at 4 mg reduced skeletal-related events in prostate cancer patients with bone metastases and urinary markers of bone resorption were statistically significantly decreased in patients who received zoledronic Acid at either dose.
Journal ArticleDOI
Skeletal complications of malignancy
TL;DR: Good prognostic factors for survival after the development of bone metastases are good histologic grade, positive estrogen receptor status, bone disease at initial presentation, a long disease free interval, and increasing age, while patients with disease that remains confined to the skeleton have a better prognosis than those with subsequent visceral involvement.